Redalpine Closes $250M Fund VIII, Its Biggest Ever

TL;DR
Zug-headquartered Redalpine has announced the final close of Redalpine Capital VIII (RAC VIII) at $250 million, oversubscribed and above its original target, making it the firm's largest fund in its 20-year history. The raise pushes Redalpine's total assets under management past $1.4 billion and drew backing from a mix of new and returning European institutional investors, including Aviva Investors, Flexstone Partners, and KfW. RAC VIII will back around 20 early-stage European companies, primarily at Seed and Series A, with a thesis centered on what the firm calls the intersection of software and science: fusion energy, AI, robotics, and biotech. First investments already include Arlequin AI, Enact Intelligence, telli, and Helical.
Key Takeaways
This is a step up, not a reset, from RAC VII. Redalpine's prior early-stage fund, RAC VII, closed at $200 million in 2024. RAC VIII's $250 million final close is a roughly 25% increase and came in above the firm's original target, which is a reasonable sign that LPs who backed the last cycle wanted back in rather than sitting it out.
The LP roster leans institutional and European. Aviva Investors, Flexstone Partners, and KfW are the three names Bloomberg confirmed as backers, a mix of an insurer-asset-manager, a private markets specialist, and Germany's state development bank. That's a notably more institutional base than many first-time or sophomore European funds can assemble, and it reflects two decades of track record rather than a debut pitch.
The science-and-software thesis is unusually literal here. Half of Redalpine's investment team are trained scientists, genomicists, physicists, and machine learning researchers, and half are operators and entrepreneurs. First checks out of RAC VIII, into a topological-neural-network threat detection startup and a robotics tactile-sensing company, read as a direct extension of that team composition rather than a thesis slide bolted onto a generalist fund.
Exits, not just markups, are doing the talking. Redalpine says 11 portfolio companies have exited since 2023, at a time when exit activity across European tech has been scarce. Combined with RAC VII's portfolio reportedly pulling in more than $1.1 billion in follow-on funding since that fund closed, the firm has real distributions and markups to point to heading into a tougher fundraising environment, not just paper gains.
Fund Overview
Fund Name: Redalpine Capital VIII (RAC VIII)
Fund Size: $250 million (final close, oversubscribed, above original target)
Stage: Early-stage, primarily leading Seed and Series A rounds
Check Size: Not disclosed; fund will back roughly 20 companies
Geography: Europe, sourced from offices in Zug, Berlin, and London
Focus: Frontier technology at the intersection of software and science, including fusion energy, AI, robotics, and biotech
Key LPs: Aviva Investors, Flexstone Partners, and KfW, described by the firm as a mix of new and returning European institutional investors
Why This Fund Matters
Redalpine has been investing since 2006, which puts RAC VIII's close in a different category from most of the funds that cross this desk. This isn't a firm proving a thesis for the first time; it's a 20-year-old shop raising its largest vehicle yet, oversubscribed, in a European fundraising market that has been broadly described as difficult for most of 2026. That combination, a bigger fund, a tougher market, and an LP base that includes a national development bank, suggests real institutional conviction rather than momentum investing.
The fund's thesis is also a useful data point on where European frontier-tech capital is actually flowing. Rather than picking a single vertical, Redalpine is spreading RAC VIII across fusion energy, AI, robotics, and biotech, categories that share long R&D timelines and genuine technical risk rather than pure go-to-market risk. That's a different bet than the software-first, capital-light model most seed funds are built around, and it requires a different kind of underwriting: the firm says it reviews more than 5,000 companies a year to find roughly 20 it believes can become category leaders, a conversion rate that only works with deep technical diligence capacity in-house.
The KfW commitment is worth flagging on its own. Germany's state development bank backing a Swiss-headquartered, pan-European frontier-tech fund is a small but real signal that sovereign and quasi-sovereign capital is willing to underwrite deep-tech venture risk at the fund level, not just through direct grants or national funds. Combined with Aviva Investors and Flexstone Partners, RAC VIII's LP base reads as a vote of confidence from exactly the kind of institutional money that has been more cautious about European venture over the past two years.
None of that erases the open questions. Redalpine hasn't disclosed individual check sizes for RAC VIII, and the 11 exits since 2023 and $1.1 billion in RAC VII follow-on funding are the firm's own reported figures rather than independently audited numbers. They're consistent with what a credible 20-company early-stage fund with a 20-year track record should be able to claim, but founders and co-investors evaluating the firm should still ask for specifics on a deal-by-deal basis.
The Team
Redalpine was founded in 2006 by Peter Niederhauser, a serial entrepreneur, and Dr. Michael Sidler, a molecular biologist; both remain active at the firm today as founding partners. The current general partner group, per the firm's own team page, is Sebastian Becker, Daniel Graf, Dr. Harald Nieder, and Dr. Oliver Pabst. Dr. Marc Moesser holds the title of partner, and Mira Kamp is partner and managing director for Germany, where Redalpine maintains a Berlin presence alongside its Zug, Switzerland headquarters and London office. Lezama Schneider is principal and head of co-investments, and Anna Seidel is principal on the firm's separate Summit Fund vehicle. Dr. Florian Bieberich and Dr. Luca Del Medico round out the investment team as associates.
The firm describes its team as split roughly evenly between trained scientists, including genomicists, physicists, and machine learning specialists, and operators and entrepreneurs, a structure it credits for giving it both the technical depth to evaluate frontier-tech claims and the operating experience to help translate them into scalable businesses.
Early Portfolio
Redalpine named four companies as RAC VIII's first investments. Arlequin AI, based in Paris, builds topological neural networks that learn from relationships between data points to help governments and organizations surface hidden threats. Enact Intelligence, based in Zurich, is developing tactile sensing technology that gives robots the ability to feel and interact with the physical world rather than relying on vision alone. telli, based in Berlin, builds AI agents that handle customer conversations end to end. Helical, based in London, is building what the firm calls a virtual AI lab for pharma, turning biological foundation models into reproducible drug discovery workflows.
What This Means for Founders
European founders working on technically deep problems, fusion, advanced robotics, biotech platforms, frontier AI infrastructure, who need investors capable of real technical diligence rather than a generalist check should have Redalpine high on their list, particularly at Seed and Series A. The firm's own framing, that it reviews thousands of companies a year to find a small number of category-defining bets, suggests a high bar but also a willingness to engage seriously with scientifically complex pitches that a software-only fund might pass on without the in-house expertise to evaluate.
The firm's multi-stage platform, which it says spans early-stage investing through IPO, also matters for founders thinking about their capital strategy beyond the first check. A fund willing to follow on through later rounds reduces the pressure to immediately find a new lead for every subsequent raise, though founders should still confirm Redalpine's actual follow-on capacity and reserve ratios for RAC VIII specifically before counting on it.
Fund Momentum Take
The headline number here is less interesting than the LP list. Plenty of European VCs are raising funds in the $200 million to $300 million range right now; fewer are doing it with a development bank and an insurance-linked asset manager both writing checks into an early-stage, deep-tech-heavy vehicle. That's the kind of LP base that tends to show up for firms with two decades of realized outcomes behind them, not for a thesis pitch, and it's a reasonable signal that institutional appetite for European frontier tech hasn't disappeared even as overall fundraising has gotten harder.
The self-reported numbers, 11 exits since 2023, $1.1 billion in RAC VII follow-on funding, are the kind of claims worth treating as a starting point rather than a verified fact, simply because they're the firm's own figures and we don't have an independent breakdown of which exits were acquisitions versus write-downs dressed up as exits, or how much of that $1.1 billion was new capital versus insider rounds. That's not a reason to doubt the fund closed at $250 million, which Bloomberg independently confirmed, but it is a reason to ask Redalpine for specifics before repeating the track-record claims as settled fact.
Our bet: the real test of RAC VIII isn't the fundraise, it's whether a fund built around fusion energy, robotics, and biotech alongside AI can keep its portfolio concentration small enough, around 20 companies, to actually deliver the kind of hands-on technical support its scientist-heavy team is supposed to provide. That model works brilliantly at $200 million. Whether it still works at $250 million with a bigger team and more LPs to answer to is the thing to watch over the next two years.
Frequently Asked Questions
How big is Redalpine Capital VIII?
RAC VIII closed at $250 million, its final close, which the firm says came in above its original fundraising target and oversubscribed. It is Redalpine's largest fund to date.
Who are Redalpine's limited partners in RAC VIII?
Bloomberg confirmed the fund drew backing from a mix of new and returning European institutional investors, naming Aviva Investors, Flexstone Partners, and KfW, Germany's state development bank, among them.
How does RAC VIII compare to Redalpine's previous fund?
Redalpine's prior early-stage fund, RAC VII, closed at $200 million in 2024. RAC VIII's $250 million represents roughly a 25% increase.
What does Redalpine invest in?
The firm backs early-stage European companies, primarily at Seed and Series A, working at what it calls the intersection of software and science, including fusion energy, AI, robotics, and biotech.
Who leads Redalpine today?
Founders Peter Niederhauser and Dr. Michael Sidler remain active as founding partners. The firm's current general partners are Sebastian Becker, Daniel Graf, Dr. Harald Nieder, and Dr. Oliver Pabst, alongside partners Dr. Marc Moesser and Mira Kamp, who also serves as managing director for Germany.
Have a fund closing to announce? Submit your fund here.
Need help raising capital? Check out our Fundraising Advisory services.
Related funds in the index
EnergyTech funds from the verified index
| Fund | Size | Stage | Location | Focus |
|---|---|---|---|---|
| Zacua Ventures Fund II | $135M USD | Pre Seed | United States | Built Environment, Manufacturing +3 |
| Course Corrected Fund II | €80M EUR | Pre Seed | Sweden | EnergyTech, Climate & Sustainability |
| Octopus Ventures Fund II | £10M GBP | Pre Seed | United Kingdom | AI/ML, Robotics & Automation +2 |
| AP Ventures Fund III | $300M USD | Seed | United Kingdom | Manufacturing, EnergyTech +3 |
| Bison Ventures Fund II | $160M USD | Pre Seed | United States | AI/ML, Digital Education (Consumer) +1 |